BROADWOOD PARTNERS, L.P.
CIK 1278386 · last filed 2026-04-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
STAA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
156 WEST 56TH STREET, 3RD FLOOR
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (OCX) Delisted | 10%+ Owner | 24,148,020 | $3.20 | $77.27M | $137.03M | 12 | 2026-04-20 |
| STAA | 10%+ Owner | 30,907,258 | $23.30 | $720.14M | -$233.92M | 30 | 2026-01-13 |
| LCTX | Director | 83,332,510 | $1.01 | $84.17M | $21.00M | 1 | 2024-02-08 |
| Asterias Biotherapeutics, Inc. (AST) Delisted | 10,584,312 | — | — | $12.42M | 1 | 2017-10-18 | |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 30,034,469 | — | — | $22.26M | 4 | 2017-10-17 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Director | 5,283,320 | — | — | -$149.77M | 3 | 2014-02-13 |
| PALOMAR MEDICAL TECHNOLOGIES LLC (PMTI) Delisted | 10%+ Owner | 5,510,046 | — | — | $8.00M | 2 | 2012-05-31 |
| COMARCO INC (CMRO) Delisted | 10%+ Owner | 2,655,910 | — | — | $3.91M | 12 | 2008-01-22 |
Recent Filings · Page 4 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-02-12 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +1,599,999 | $6.00M | EDGAR |
| 2017-10-18 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +4,776,924 | $12.42M | EDGAR |
| 2017-10-17 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Buy (P) | +8,076,921 | $21.00M | EDGAR |
| 2017-08-02 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Buy (P) | +450,000 | $1.26M | EDGAR |
| 2016-05-25 | STAA | Buy (P) | +233,526 | $1.21M | EDGAR |
| 2016-02-09 | STAA | Buy (P) | +275,310 | $1.72M | EDGAR |
| 2016-02-01 | STAA | Buy (P) | +197,949 | $1.28M | EDGAR |
| 2016-01-15 | STAA | Buy (P) | +407,175 | $2.74M | EDGAR |
| 2015-09-29 | STAA | Buy (P) | +933,297 | $6.61M | EDGAR |
| 2014-02-13 | QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | Sell (S) | −255,000 | -$17.62M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.